Latest News

Largest Human Study on Krill Published in Peer-Reviewed Publication

Researchers from Aker BioMarine Antarctic AS have announced the publication of a new study on Superba(TM) Krill oil in the February 2014 edition of Nutrition Research.

The study investigated the effects of Superba(TM) Krill on blood lipids in subjects with “borderline high” or “high” triglyceride (TG) levels. A total of 300 volunteers were divided into five groups and supplemented with krill oil at either 0.5, 1, 2 or 4 grams per day or placebo (olive oil). The subjects included in the study had blood TG values between 150 and 499 mg/dL. Blood lipids were measured at baseline, 6 weeks and 12 weeks of treatment.

Relative to subjects in the placebo group, those administered krill oil had a statistically significant 10.2% reduction in serum TG levels. Moreover, LDL-C levels were not increased in the krill oil groups relative to the placebo group, an important finding considering an increase in LDL-C has been observed in some fish oil trials.

“It is remarkable that krill oil, providing on average less than 400 mg per day of EPA and DHA, produced a significant 10% reduction in serum triglyceride levels,” said Dr. William Harris, PhD, Professor of Medicine, University of South Dakota School of Medicine, and co-inventor of the HS Omega-3 Index Blood Test, and member of the Aker BioMarine Antarctic Science Board.

The outcome of this pooled analysis suggests that krill oil is effective in reducing a cardiovascular risk factor. However, owing to the individual fluctuations of TG concentrations measured, a study with more individual measurements per treatment group is needed to increase the confidence of these findings.

Study coordinator Kjetil Berge, PhD, R&D Director, Aker BioMarine Antarctic, commented: “This was a large undertaking and we are pleased with the results. It gives us added confidence to pursue similar endpoints with similar subject sizes in future studies.”

Another notable aspect of the study was Superba(TM) Krill’s ability to raise subjects’ omega-3 index, particularly among those taking the highest amounts. “It is interesting to point out that with the highest dose of krill oil, the omega-3 index increased by 70%. Even with the lowest dose of 500 mg krill oil, there was a significant increase. Thus, this might have an impact on the risk of sudden cardiac death, which has been demonstrated in several studies during the last decade,” said Dr. Clemens Von Schacky, co-inventor of the HS Omega-3 Index Blood test.

Reference: Berge, K. et al., “Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels.”

Citation: Nutrition Research, February 2014;34(2):126-133.

Access to Full Paper:


About SuperbaTM Krill

SuperbaTM Krill is a pure, natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant astaxanthin. The uniqueness of SuperbaTM Krill Oil is that the omega-3 fatty acids are provided in phospholipid form.  In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of SuperbaTM Krill Oil.


About Aker BioMarine

Aker BioMarine is an integrated biotechnology company dedicated to the sustainable harvesting of krill and development of krill-derived biotech products. The company supplies biomarine ingredients through an optimized value chain from raw materials to customers. Aker BioMarine’s SuperbaTM Krill products are provided with 100% traceability from sea to shelf.  Only Aker’s krill fishery has been awarded Marine Stewardship Council (MSC) Certification.


For more information, please contact:

Matts Johansen, COO, Aker BioMarine Antarctic, +47-916-30-120


North America:  

Todd Norton, +1 206-855-6736 x 215



Roar Hernes, +47-241-30-123  



Chris McReynolds, +1 206-660-6756



Lalen Dogan, +61-3-9999-1112



Andreas Thorud, +86-21-6035-6300



Atul Barmann, +91-2266915757